AIMS: Cryoballoon technology is a promising technique in paroxysmal atrial fibrillation (AF) ablation. However, success rates in patients with persistent AF have not been convincing. There is a trend toward performing more extensive procedures that are referred to as 'pulmonary vein isolation plus.' To combine pulmonary vein isolation (PVI) and antral substrate modification, we used both the 23-mm and 28-mm cryoballoon in a single approach in patients with persistent AF. METHODS AND RESULTS: 33 consecutive patients (26 men, age 60 ± 10 years, LA size 44 ± 5 mm) with persistent AF were prospectively included. All patients underwent the "double balloon strategy:" at least two applications at each pulmonary vein (PV) using the smaller 23-mm balloon to isolate the PV at the ostial level plus at least one additional freeze by the 28-mm balloon at the wide PV antral level. 7-day Holter monitors were performed during follow-up at 1, 3, 6, 9, 12, 18 and 24 months post-ablation. 131 of 133 PVs were targeted and isolated (98.4 %). A mean of 14 ± 2 cryoballoon applications per patient or 3.5 ± 1.5 applications per vein were performed. After a single procedure and mean follow-up of 15 ± 3 months, 69.7 % of patients remained in sinus rhythm (3-month blanking period). There were no major complications. CONCLUSIONS: In persistent AF, the "double balloon strategy;" combining the small and large cryoballoon allowed ostial PV isolation followed by antral cryoablation is feasible, safe and associated with a favorable outcome.
AIMS: Cryoballoon technology is a promising technique in paroxysmal atrial fibrillation (AF) ablation. However, success rates in patients with persistent AF have not been convincing. There is a trend toward performing more extensive procedures that are referred to as 'pulmonary vein isolation plus.' To combine pulmonary vein isolation (PVI) and antral substrate modification, we used both the 23-mm and 28-mm cryoballoon in a single approach in patients with persistent AF. METHODS AND RESULTS: 33 consecutive patients (26 men, age 60 ± 10 years, LA size 44 ± 5 mm) with persistent AF were prospectively included. All patients underwent the "double balloon strategy:" at least two applications at each pulmonary vein (PV) using the smaller 23-mm balloon to isolate the PV at the ostial level plus at least one additional freeze by the 28-mm balloon at the wide PV antral level. 7-day Holter monitors were performed during follow-up at 1, 3, 6, 9, 12, 18 and 24 months post-ablation. 131 of 133 PVs were targeted and isolated (98.4 %). A mean of 14 ± 2 cryoballoon applications per patient or 3.5 ± 1.5 applications per vein were performed. After a single procedure and mean follow-up of 15 ± 3 months, 69.7 % of patients remained in sinus rhythm (3-month blanking period). There were no major complications. CONCLUSIONS: In persistent AF, the "double balloon strategy;" combining the small and large cryoballoon allowed ostial PV isolation followed by antral cryoablation is feasible, safe and associated with a favorable outcome.
Authors: Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin Journal: Heart Rhythm Date: 2007-04-30 Impact factor: 6.343
Authors: Michel Haïssaguerre; Mélèze Hocini; Prashanthan Sanders; Frederic Sacher; Martin Rotter; Yoshihide Takahashi; Thomas Rostock; Li-Fern Hsu; Pierre Bordachar; Sylvain Reuter; Raymond Roudaut; Jacques Clémenty; Pierre Jaïs Journal: J Cardiovasc Electrophysiol Date: 2005-11
Authors: Stephan Willems; Hanno Klemm; Thomas Rostock; Benedikt Brandstrup; Rodolfo Ventura; Daniel Steven; Tim Risius; Boris Lutomsky; Thomas Meinertz Journal: Eur Heart J Date: 2006-06-16 Impact factor: 29.983
Authors: Gian B Chierchia; Carlo de Asmundis; Antonio Sorgente; Gaetano Paparella; Andrea Sarkozy; Stephan-Andreas Müller-Burri; Lucio Capulzini; Yoshinao Yazaki; Pedro Brugada Journal: J Cardiovasc Med (Hagerstown) Date: 2011-03 Impact factor: 2.160
Authors: Hakan Oral; Bradley P Knight; Hiroshi Tada; Mehmet Ozaydin; Aman Chugh; Sohail Hassan; Christoph Scharf; Steve W K Lai; Radmira Greenstein; Frank Pelosi; S Adam Strickberger; Fred Morady Journal: Circulation Date: 2002-03-05 Impact factor: 29.690
Authors: Hakan Oral; Aman Chugh; Kentaro Yoshida; Jean F Sarrazin; Michael Kuhne; Thomas Crawford; Nagib Chalfoun; Darryl Wells; Warangkna Boonyapisit; Srikar Veerareddy; Sreedhar Billakanty; Wai S Wong; Eric Good; Krit Jongnarangsin; Frank Pelosi; Frank Bogun; Fred Morady Journal: J Am Coll Cardiol Date: 2009-03-03 Impact factor: 24.094
Authors: Andreas Rillig; Tina Lin; Boris Schmidt; Britta Feige; Christian Heeger; Jascha Wegner; Erik Wissner; Andreas Metzner; Anita Arya; Shibu Mathew; Peter Wohlmuth; Feifan Ouyang; Karl-Heinz Kuck; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2015-07-22 Impact factor: 5.460
Authors: Reza Wakili; Sebastian Clauss; Viola Schmidt; Michael Ulbrich; Anton Hahnefeld; Franziska Schüssler; Johannes Siebermair; Stefan Kääb; Heidi L Estner Journal: Clin Res Cardiol Date: 2013-10-06 Impact factor: 5.460
Authors: Andreas Rillig; Boris Schmidt; Britta Feige; Erik Wissner; Andreas Metzner; Anita Arya; Shibu Mathew; Hisaki Makimoto; Peter Wohlmuth; Feifan Ouyang; Karl-Heinz Kuck; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2013-07-30 Impact factor: 5.460